Melega C, Balducci M, Bulletti C, Galassi A, Jasonni V M, Flamigni C
Department of Obstetrics and Gynecology, University of Bologna, Italy.
Ann N Y Acad Sci. 1991;622:256-65. doi: 10.1111/j.1749-6632.1991.tb37869.x.
The unpredictable response of endometriosis to steroids and its recurrence after therapy, led us to hypothesize a possible further control of this pathology by factors other than steroids. The presence of estrogen, progesterone and epidermal growth factor receptors (ER, PR, EGFr) was evaluated using immunohistochemistry before and after therapy with Danazol or a gonadotropin-releasing hormone analogue (GnRHa), Buserelin. EGFr, ER and PR were present in 100% of endometrial specimens, and in 71%, 29% and 49% of endometriotic implants, respectively. Danazol and GnRHa reduced immunohistochemical staining for EGFr antisera in the endometrial and endometriotic specimens. About 21% of endometriosis were EGFr positive and ER negative, suggesting a potential role of epidermal growth factor in growth and maintenance of endometrial ectopia.
子宫内膜异位症对类固醇药物反应不可预测且治疗后易复发，这使我们推测可能存在除类固醇以外的其他因素对该病症进行进一步控制。在使用达那唑或促性腺激素释放激素类似物（GnRHa）布舍瑞林治疗前后，采用免疫组织化学方法评估雌激素、孕激素和表皮生长因子受体（ER、PR、EGFr）的表达情况。EGFr、ER和PR分别存在于100%的子宫内膜标本以及71%、29%和49%的子宫内膜异位植入物中。达那唑和GnRHa降低了子宫内膜和子宫内膜异位标本中EGFr抗血清的免疫组织化学染色。约21%的子宫内膜异位症患者EGFr呈阳性而ER呈阴性，提示表皮生长因子在子宫内膜异位灶的生长和维持中可能发挥作用。
